# Rare disease gene to candidate drugs: GBA1 in one query

> How to go from a rare disease gene to candidate drugs: one GBA1 query returns HPO, OMIM, Orphanet and Open Targets disease links, as of 2026-11-06.

Data as of 2026-11-06 · Published 2026-11-09 · Updated 2026-11-06 · https://bioq.bio/blog/en/howto-rare-disease-gene-to-candidate-drug-gba1

![BioQ result page for the query GBA1 listing linked diseases from HPO, OMIM and Orphanet next to Open Targets association scores](https://bioq.bio/blog/img/howto-rare-disease-gene-to-candidate-drug-gba1/en/hero.webp)

A single GBA1 query in BioQ links the gene to 13 diseases in HPO, OMIM and Orphanet, and Open Targets lists 1336 associated diseases. The top Open Targets entry is Gaucher disease at a score of 0.814, with Parkinson disease at 0.77. This is the disease-side starting point for a rare disease gene to candidate drugs workflow. The data are as of 2026-11-06.

## What we asked: a rare disease gene to candidate drugs starting point

The task is common in rare-disease work. You have a gene, here GBA1, and you need to know which conditions it is tied to before you ask which compounds act on it. Getting this wrong has a cost. If you build a drug search around one phenotype and miss that the gene also carries a polygenic risk signal in another disease, you scope the project too narrowly.

The manual route is to open HPO, OMIM and Orphanet for the gene-disease links, then open Open Targets for ranked associations, and then reconcile disease names and identifiers between them. Each of those sites uses its own naming and its own IDs.

The query we ran in BioQ is the gene symbol alone: GBA1.

## What BioQ returned

The query drew on 2 distinct resources and ran 3 engine queries in 0.17 seconds in total. That figure is the measured engine time only. It does not include the time you spend reading and judging the output.

The first block lists diseases linked to GBA1 in HPO, OMIM and Orphanet. There are 13 in total, and the table shows 8.

| Disease | Association | ID |
|---|---|---|
| Lewy body dementia | polygenic | OMIM:127750 |
| late-onset Parkinson disease | polygenic | OMIM:168600 |
| Gaucher disease type I | mendelian | OMIM:230800 |
| Gaucher disease type II | mendelian | OMIM:230900 |
| Gaucher disease type III | mendelian | OMIM:231000 |
| Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome | mendelian | OMIM:231005 |
| Gaucher disease perinatal lethal | mendelian | OMIM:608013 |
| Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome | unknown | ORPHA:2072 |

The second block comes from Open Targets. It ranks diseases by association score, which runs from 0 to 1. There are 1336 associated diseases in total, and the table shows the top 6.

| Disease | Association score | Evidence items |
|---|---|---|
| Gaucher disease | 0.814 | 3055 |
| Gaucher disease type I | 0.811 | 419 |
| Gaucher disease type II | 0.807 | 166 |
| Gaucher disease type III | 0.799 | 139 |
| Gaucher disease perinatal lethal | 0.774 | 82 |
| Parkinson disease | 0.77 | 3174 |

## What it means and how to read it

**Two kinds of association appear.** In the HPO, OMIM and Orphanet block, the Gaucher disease entries are labelled mendelian. Lewy body dementia and late-onset Parkinson disease are labelled polygenic. For a rare disease gene to candidate drugs question, this tells you the gene has a monogenic disease family and a risk-factor role in a more common neurodegenerative one. Those are different patient populations and may need different questions.

**The same disease can appear under two ID systems.** The Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome is listed twice: once as OMIM:231005 (mendelian) and once as ORPHA:2072 (association "unknown"). These are one condition in two catalogues, not two findings. Count it once when you tally diseases.

**The Open Targets score is not the evidence count.** Gaucher disease scores 0.814 on 3055 evidence items. Parkinson disease scores 0.77 on 3174 evidence items, which is more items but a lower score. The score reflects how the evidence is weighted and combined, not the raw volume. Do not read the score as disease severity, as patient numbers, or as a measure of how easy the gene is to drug.

**What to do next.** With the disease list in hand, you can scope the drug question. Decide whether you are working on the Gaucher subtypes (type I, type II, type III, perinatal lethal), on Parkinson disease with a GBA1 background, or on both. Then run follow-up queries on compounds and trials for GBA1, for example by asking BioQ about its known ligands or about trials listing the gene or the disease. If you are interested in chaperone therapy as a mechanism, name it in that follow-up query so the results can be filtered to it. The query above does not return any compounds, so any drug list must come from that next step, with its own sources shown.

## How to reproduce it in BioQ

1. Open BioQ and start a new search.
2. Enter the gene symbol exactly as written, in Latin letters and with the digit 1 at the end:

```text
GBA1
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DGBA1)

3. Read the disease-link block first and note which entries are mendelian and which are polygenic.
4. Read the Open Targets block and compare score with evidence items for each disease.
5. Check the source named under each block. Every answer in BioQ names its source, so you can trace a row back to HPO, OMIM, Orphanet or Open Targets.
6. Use the diseases you chose as the input to a follow-up query on compounds or trials.

## Limits: what the data do not show

- **No drugs here.** This result covers diseases only. It does not say which compounds bind or modulate GBA1, and it does not say whether any has been tested in patients.
- **Tables are truncated.** The gene-disease block shows 8 of 13 diseases and the Open Targets block shows 6 of 1336. Diseases beyond the displayed rows are not in the tables above.
- **Association is not causation.** An Open Targets score summarises evidence of association. It does not show that GBA1 variation causes a given disease, and it does not show direction of effect.
- **Polygenic labels carry little detail.** The label says GBA1 contributes to risk in Lewy body dementia and late-onset Parkinson disease. It does not give effect size, which variants are involved or how the risk differs between populations.
- **Timing covers the engine only.** The 0.17 seconds measures the 3 engine queries. It says nothing about how long expert review takes.
- **Snapshot.** The results reflect releases as of 2026-11-06. Later releases of these resources may change the lists and scores.

Nothing in this article is medical advice or a recommendation for treatment.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (3 queries, 0.2 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/gene_disease`, `/ot_association`

Run the same query yourself: [GBA1](https://bioq.bio/login?next=%2Fapp%23q%3DGBA1)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`GBA1`](https://bioq.bio/login?next=%2Fapp%23q%3DGBA1)

## Frequently asked questions

### How many diseases is GBA1 linked to in HPO, OMIM and Orphanet?

BioQ returned 13 diseases for GBA1 from HPO, OMIM and Orphanet, as of 2026-11-06. The table on the page shows 8 of them, including Gaucher disease types I, II and III and late-onset Parkinson disease.

### What is the top Open Targets disease for GBA1?

Gaucher disease has the highest association score at 0.814, with 3055 evidence items. Open Targets lists 1336 associated diseases for GBA1 in total, and BioQ shows the top 6.

### Is GBA1 linked to Parkinson disease in these data?

Yes. Late-onset Parkinson disease (OMIM:168600) is labelled polygenic in the HPO, OMIM and Orphanet block. Open Targets scores Parkinson disease at 0.77 with 3174 evidence items. These are association data and do not show causation.

### Does the GBA1 query return candidate drugs?

No. The query returned diseases from 2 distinct resources and no compounds. Drug and trial information needs a follow-up query once you have chosen which disease to work on.

### How long did the GBA1 query take?

The measured engine time was 0.17 seconds in total across 3 engine queries. That covers the engine only, not the time needed to read and interpret the results.

## Sources

- Dataset: [Human Phenotype Ontology, OMIM, Orphanet](https://hpo.jax.org/)
- Dataset: [Open Targets Platform (target-disease associations)](https://platform.opentargets.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
